Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical ...

Samsung Bioepis Co. and Teva Pharmaceutical Industries (TEVA have entered into a license, development and commercialization agreement ...

Pharmaceutical Industries announced that the companies have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis’ biosimilar to Soliris in the United States ...

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH),atypical hemolytic uremic syndrome (aHUS)andgeneralized myasthenia gravis (gMG)in the U ...

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...

Korean firms seek US FDA approval for new anticancer drugs and biosimilars Korean pharmaceutical companies renewed their ...

Park emphasized, 'The year 2025 will mark the 10th anniversary of the transformation of the institute, and it will be a ...

For more information, or to register for this event, visit The New Era of CDx in Oncology: Adapting Clinical Research Strategy to Evolving Regulations.

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...

Vistagen , a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in a repeat dose study of ...

The South Korean firm just agreed to buy Biogen out of their biosimilar joint venture – Samsung Bioepis – for $2.3 billion. The two companies have been partnered on Samsung Bioepis for the ...

Nonetheless, the pricing of Humira biosimilars from Sandoz, Amgen (Amgevita and Solymbi), Boehringer Ingelheim (Cyltezo), Samsung Bioepis (Imraldi) will be key, with health systems keen to benefit ...